温馨提示:本文中所涉及的信息旨在传递医药前沿信息和研究进展,不涉及诊疗方案推荐,临床上请遵从医生或其他医疗卫生专业人士的意见与指导。
封面图片:摄图网 稿定设计
[1]Qin S, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online October 05, 2023. doi:10.1001/jamaoncol.2023.4003.
[2]Richard S. Finn, et al. 2023 ASCO GI abstract 495.
[3]Minshan Chen et al.2022 ESMO IO Abstract 165P
[4]蒋仕伍,彭晓燕,陈均源,等. TACE联合替雷利珠单抗治疗中晚期原发性肝癌的临床价值[J]. 肝脏,2024,29(6):676-680. DOI:10.3969/j.issn.1008-1704.2024.06.015.










